Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 4, 1998, Pages 304-312

  Veroff, Amy E ^a   Bodick, Neil C ^b   Offen, Walter W ^b   Sramek, John J ^a   Cutler, Neal R ^a,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NONE   (United States)

Author keywords

ADAS cog; Alzheimer disease; Cognition scales; Computerized Neuropsychological Test Battery; Rating scales; Xanomeline

Indexed keywords

MUSCARINIC M1 RECEPTOR; XANOMELINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RATING SCALE; RECALL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS;

EID: 0032458542     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199812000-00010     Document Type: Article

References (31)

1. Bodick NC, DeLong AF, Bonate PL, Gillespie T, Henry DP, Satterwhite JH. Xanomeline, a specific m1 agonist: early clinical studies. In: Giacobini E, Becker R, eds. Alzheimer disease: therapeutic strategies. Boston: Birkhäuser 1994:234-8.
2. Bodick NC, Offen WW, Levey AI, et al. The effects of xanomeline, an M1-selective muscarinic agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-73.
3. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 1994;269:282-9.
4. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Statistician 1981;35:124-33.
5. Coyle JT, Price DL, Delong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
6. Cutler NR, Shrotriya RC, Sramek JJ, et al. The use of the computerized neuropsychological test battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Ann NY Acad Sci 1993;695:332-6.
7. 1-receptor agonists: potential in the treatment of Alzheimer's disease. CNS Drugs 1995;3:467-81.
8. Davies P, Maloney AJF. Selective loss of central cholinergic neurons of the Alzheimer's type. Lancet 1976;2:1403.
9. Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer's type dementia brains. Brain Res 1997;138:385-92.
10. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlates. Ann Neurol 1992;32:625-32.
11. Delis DC, Massman PJ, Butters N, et al. Profiles of demented and amnesic patients on the California Verbal Learning Test: Implications for the assessment of memory disorders. Psychol Assess 1991;3:19-26.
12. Ferris S, Crook T, Sathananthan G, Gershon S. Reaction time as a diagnostic measure in senility. J Am Geriatr Soc 1976;12:529-33.
13. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
14. Goodglass H, Kaplan E. Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
15. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
16. Kramer JH, Levin BE, Brandt J, Delis DC. Differentiation of Alzheimer's, Huntington's and Parkinson's disease patients on the basis of verbal learning characteristics. Neuropsychology 1989;3: 111-20.
17. Lehericy S, Hirsch EC, Cervera P, et al. Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer's disease. Proc Natl Acad Sci USA 1989;86:8580-4.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-44.
19. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-9.
20. Pirozzolo FJ, Christensen KJ, Ogle KM, Hansch EC, Thompson WG. Simple and choice reaction time in dementia: clinical implications. Neurobiol Aging 1981;2:113-7.
21. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
22. Rosen WG, Mohs KS, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
23. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
24. 1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 1992;35:2274-83.
25. 1 receptors. J Pharmacol Exp Ther 1994;269:271-81.
26. Sims NR, Bowen DM, Smith CC, et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1981;1:333-6.
27. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995;35:800-6.
28. Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
29. Veroff AE, Cutler NR, Sramek JJ, Prior PL, Mickelson W, Hartman JK. A new assessment tool for neuropsychopharmacologic research: the computerized neuropsychological test battery. J Geriatr Psychiatry Neurol 1991;4:211-7.
30. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
31. Wilcox GK, Esiri MM, Bowen DM, et al. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57: 407-17.